This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Accelrys And Pfizer Extend Agreement For Global Deployment Of Scientific Innovation Lifecycle Management Software

SAN DIEGO, May 7, 2013 /PRNewswire/ -- Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management software, announced today that Pfizer, Inc. (NYSE: PFE) has signed a three-year contract with Accelrys, extending the companies' long-standing strategic partnership.  The agreement continues the global deployment of the Accelrys Enterprise Platform, Pipeline Pilot, Cheminformatics Suite and Modeling & Simulation software to Pfizer researchers worldwide.

(Logo:  http://photos.prnewswire.com/prnh/20120416/MM88629LOGO)

The scientifically aware Accelrys Enterprise Platform offers access to broad scientific informatics solutions across different domains while simplifying integration into existing IT environments. The Pipeline Pilot scientific workflow authoring application enables scientific services that automate the process of accessing, analyzing and reporting scientific data for sharing across the scientific community. Leveraging the Accelrys Cheminformatics Suite, scientists can register, search, mine, analyze and report on chemical structures and reactions, chemically modified sequences and associated information such as inventory, assay and analytical results. Accelrys Modeling and Simulation software accelerates collaborative research and development of innovative health care treatments through the use of predictive science.

Accelrys President and Chief Executive Officer Max Carnecchia described the profound challenges that are requiring pharmaceutical companies to transform their businesses to remain competitive, saying, "From externalization to cost pressures to regulatory compliance, today's industry trends are making it more difficult for pharmaceutical organizations to deliver innovative products to market quickly and cost-effectively. As Pfizer well knows, overcoming these challenges demands both disease area and technology expertise. Accelrys' integrated technology solutions ― built with deep scientific understanding ― are helping valued customers like Pfizer grow their businesses to meet the demands of today and tomorrow."

About Accelrys, Inc.Accelrys (NASDAQ:ACCL), a leading provider of scientific innovation lifecycle management software, supports industries and organizations that rely on scientific innovation to differentiate themselves. The industry-leading Accelrys Enterprise Platform provides a broad, flexible scientific solution optimized to integrate the diversity of science, experimental processes and information requirements across the research, development, process scale-up and early manufacturing phases of product development. By incorporating capabilities in applications for modeling and simulation, enterprise lab management, workflow and automation, and data management and informatics, Accelrys enables scientific innovators to access, organize, analyze and share data in unprecedented ways, ultimately enhancing innovation, improving productivity and compliance, reducing costs and speeding time from lab to market.

Accelrys solutions are used by more than 1,300 companies in the pharmaceutical, biotechnology, energy, chemicals, aerospace, consumer packaged goods and industrial products industries. Headquartered in San Diego, Calif., Accelrys employs more than 200 full-time PhD scientists. For more information about Accelrys, visit www.accelrys.com.

Related Links Accelrys Website Follow Accelrys on Twitter Friend Accelrys on Facebook Accelrys' YouTube Channel Connect with Accelrys on LinkedIn

SOURCE Accelrys, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,001.22 -38.27 -0.22%
S&P 500 1,988.40 -3.97 -0.20%
NASDAQ 4,538.5510 +6.4470 0.14%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs